→ Allergan’s move to try and steer around an IPR review of its patents for its $1.5 billion drug Restasis by handing them over to an Indian tribe for safekeeping was tailor made for public controversy. And lawmakers have proved obliging. Now a bipartisan group of House members are setting up a probe of the deal, which relies on the sovereign immunity of the Saint Regis Mohawk tribe to block the IPR. Allergan CEO Brent Saunders wants this to be a fight about the IPR process — what he’s wound up with is a PR battle with almost no chance of winning.
→ Salt Lake City-based Recursion Pharmaceuticals raised $60 million for its AI work in drug discovery. Recursion says it’s building the “world’s largest biological image dataset.” Data Collective led the Series B.
→ Gilead has offered more Phase III data in support of its HIV cocktail containing bictegravir. The combo is currently under review at the FDA.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription